16th December 2020,
Sport Integrity Australia acknowledges the decision of Rugby Australia’s Anti-Doping Judicial Committee to sanction athlete Baxter King for the presence of a prohibited substance and its metabolite, and the use and possession of a prohibited substance.
Mr King returned an Adverse Analytical Finding (AAF) from an out-of-competition doping control test on 2 April 2019.
His sample was analysed at the Australian Sports Drug Testing Laboratory, part of the National Measurement Institute, which detected the presence of Di-Hydroxy LGD-4033 (metabolite of LGD-4033) and LGD-4033.
LGD-4033 is prohibited in and out-of-competition under the S1 Class of Anabolic Agents.
Rugby Australia imposed a four-year ban on Mr King commencing on 14 May 2019.
Mr King will be eligible to return to competition on 14 May 2023.
Additional information on the prohibited substance
LGD-4033, originally developed for the treatment of muscle wasting conditions such as aging, osteoporosis, muscular dystrophy and cancer, is promoted as a selective non-steroidal anabolic agent.
It is claimed to be a substance that induces muscle (and bone) growth without the side effects associated with steroid use. However, information on the safety of LGD-4033 is scarce due to a lack of medium and long-term clinical trials - hence the medium and long-term health impacts are unknown.
It should be noted that a number of Selective Androgen Receptor Modulators (SARMs) have associated health-risks, particularly for the heart and liver.
The original article can be found here.